Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.76 |
| ▸ | RAB9A | P51151 | 3/20 | 0.76 |
| ▸ | HSD17B3 | P37058 | 8/20 | 0.66 |
| ▸ | GAA | P10253 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | ABL1 | P00519 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | ALPI | P09923 | 1/20 | 0.61 |
| ▸ | ALPG | P10696 | 1/20 | 0.61 |
| ▸ | APEX1 | P27695 | 1/20 | 0.61 |
| ▸ | CASP3 | P42574 | 1/20 | 0.61 |
| ▸ | RECQL | P46063 | 1/20 | 0.61 |
| ▸ | BLM | P54132 | 1/20 | 0.61 |
| ▸ | CASP7 | P55210 | 1/20 | 0.61 |
| ▸ | CASP6 | P55212 | 1/20 | 0.61 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.61 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10964996 | 0.94 | NPC1 (0.73) | NPC1RAB9AHSD17B3GAAKDM4E | |
| SCHEMBL2392675 | 0.87 | NPC1 (0.68) | NPC1RAB9AHSD17B3GAAKDM4E | |
| SCHEMBL8733595 | 0.87 | NPC1 (1.00) | NPC1RAB9AHSD17B3GAAKDM4E | |
| SCHEMBL124008 | 0.87 | NPC1 (0.91) | NPC1RAB9AHSD17B3GAAKDM4E | |
| SCHEMBL8519713 | 0.85 | NPC1 (0.86) | NPC1RAB9AHSD17B3GAAKDM4E | |
| SCHEMBL8614024 | 0.85 | NPC1 (0.86) | NPC1RAB9AHSD17B3GAAKDM4E | |
| SCHEMBL10341614 | 0.85 | NPC1 (0.86) | NPC1RAB9AHSD17B3GAAKDM4E | |
| SCHEMBL8622942 | 0.85 | NPC1 (0.86) | NPC1RAB9AHSD17B3GAAKDM4E | |
| SCHEMBL10341631 | 0.85 | NPC1 (0.86) | NPC1RAB9AHSD17B3GAAKDM4E | |
| SCHEMBL7163686 | 0.85 | NPC1 (0.86) | NPC1RAB9AHSD17B3GAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3041475-B1 | PYRAZOLO[1,5-A]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS INC (US) | 2024-10-09 | — | — | EP | disclosed |
| US-20230382931-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2023-11-30 | — | — | US | disclosed |
| US-20230382931-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2023-11-30 | — | — | US | disclosed |
| US-20230382931-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2023-11-30 | — | — | US | disclosed |
| US-20230117570-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2023-04-20 | — | — | US | disclosed |
| EP-3572410-B1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2022-07-20 | — | — | EP | disclosed |
| EP-3585775-B1 | AZETIDINE COMPOUNDS AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS | SANOFI SA (FR) | 2022-04-06 | — | — | EP | disclosed |
| US-20210054008-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2021-02-25 | — | — | US | disclosed |
| US-20210054008-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2021-02-25 | — | — | US | disclosed |
| US-10822360-B2 | Dioxolane analogues of uridine for the treatment of cancer | MEDIVIR AB (SE) | 2020-11-03 | — | — | US | disclosed |
| US-5952360-A | Method for treating neuropathic pain | ELI LILLY AND COMPANY (US) | 1999-09-14 | — | — | US | disclosed |
| US-5942530-A | Method for treating pain | ELI LILLY AND COMPANY (US) | 1999-08-24 | — | — | US | disclosed |
| WO-1999018091-A1 | NOVEL COMPOUNDS USEFUL AS NEURO-PROTECTIVE AGENTS | ELI LILLY AND COMPANY (US) | 1999-04-15 | — | — | WO | disclosed |
| EP-0908186-A2 | Method for treating pain | ELI LILLY AND COMPANY (US) | 1999-04-14 | — | — | EP | disclosed |
| EP-0908180-A2 | Use of phenyl oxazole or phenyl thiazole derivatives for treating pain | ELI LILLY AND COMPANY (US) | 1999-04-14 | — | — | EP | disclosed |
| EP-0906755-A2 | Use of phenyl oxazole or phenyl thiazole derivatives for treating neuropathic pain | ELI LILLY AND COMPANY (US) | 1999-04-07 | — | — | EP | disclosed |
| WO-1999009980-A1 | METHOD FOR TREATING PAIN | ELI LILLY AND COMPANY (US) | 1999-03-04 | — | — | WO | disclosed |
| WO-1998057928-A1 | ELEVATION OF HDL CHOLESTEROL BY 2-(4-CHLORO -1-ARYL-BUTYLIDENE) -HYDRAZINECARBOTHIOAMIDES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1998-12-23 | — | — | WO | disclosed |
| US-4364949-A | BACTERICIDE, FUNGICIDE | CIBA-GEIGY CORPORATION (US) | 1982-12-21 | — | — | US | disclosed |
| EP-0031795-A1 | Hydroxyphenyl ketones | CIBA-GEIGY AG (CH) | 1981-07-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230117570-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | ADORA3, DUT, NT5C | NPC1 2748/4885RAB9A 3132/4885HSD17B3 1220/4885 |
| US-20210054008-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | ADORA3, DUT, NTPCR | NPC1 2683/4885RAB9A 3170/4885HSD17B3 1342/4885 |
| US-20230382931-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | ADORA3, DUT, NTPCR | NPC1 2683/4885RAB9A 3170/4885HSD17B3 1342/4885 |
| US-10822360-B2 | Dioxolane analogues of uridine for the treatment of cancer | ADORA3, DUT, NTPCR | NPC1 2683/4885RAB9A 3170/4885HSD17B3 1342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.